Deskbird, a Swiss software-as-a-service (SaaS) workplace management company announced its USD 13 million Series A financing round with ALSTIN Capital and AVP (AXA Venture Partners) as investors. The Series A financing round was joined by existing
Tags :Maurus Winzap
AMAG Leasing has successfully placed two tranches of green bonds totaling CHF 365 million comprising a tranche of CHF 175,000,000 with maturity in 2026 and a coupon of 2.7300% as well as a tranche of CHF 190,000,000 with maturity in 2029
UBS Switzerland has acted as mandated lead arranger, sole bookrunner, coordinator, agent and lender in connection with the renewal of the CHF 100 million revolving credit facility agreement with an increase option of CHF 50 million for
Walder Wyss is acting as legal counsel to Tradeplus24 (TP24), a Zurich-based FinTech SME lender, on its successful completion of a significant debt financing round, raising CHF 400 million. The funding was secured through a CHF 355
Cornèr Banca successfully completed its inaugural issuance of CHF 150,000,000 Senior Unsecured Bonds with a maturity date in 2025 and a coupon of 3.00%. The Bonds will be listed on the SIX Swiss Exchange. UBS Investment Bank
Walder Wyss provided legal counsel to UBS Switzerland and a consortium of 21 lenders on a new CHF 700 million multicurrency credit facility agreement for On Holding (NYSE: ONON) and its subsidiaries, On AG and On Inc.,
AMAG Leasing issued CHF 170 million Green Bonds with a maturity date in 2026 and a coupon of 2.625%. The Green Bonds will be listed at the SIX Swiss Exchange. Zürcher Kantonalbank and UBS Investment Bank acted
Walder Wyss advised a banking syndicate led by Zürcher Kantonalbank as mandated lead arranger, bookrunner, coordinator and agent on the new CHF 150 million credit facility agreement for Bauwerk Group. With a turnover of around
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
The CABB Group has successfully concluded its refinancing round. New bonds with a total volume of EUR 670 million and terms until 2028 were successfully placed with institutional investors. The issue comprises two tranches: EUR 420 million with
